109,421 Shares in Harrow, Inc. $HROW Acquired by Blackhawk Capital Partners LLC

Blackhawk Capital Partners LLC bought a new stake in Harrow, Inc. (NASDAQ:HROW) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 109,421 shares of the company’s stock, valued at approximately $5,272,000. Harrow makes up approximately 2.1% of Blackhawk Capital Partners LLC’s portfolio, making the stock its 10th biggest holding. Blackhawk Capital Partners LLC owned 0.30% of Harrow at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Raymond James Financial Inc. acquired a new stake in shares of Harrow in the 2nd quarter valued at $48,000. State of Alaska Department of Revenue purchased a new position in Harrow in the third quarter valued at $83,000. Tower Research Capital LLC TRC raised its stake in Harrow by 345.0% in the second quarter. Tower Research Capital LLC TRC now owns 3,373 shares of the company’s stock valued at $103,000 after buying an additional 2,615 shares in the last quarter. Tripletail Wealth Management LLC purchased a new stake in Harrow during the 3rd quarter worth about $221,000. Finally, Apollon Wealth Management LLC acquired a new position in shares of Harrow during the 3rd quarter worth about $226,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. B. Riley reissued a “buy” rating and set a $74.00 target price (up previously from $70.00) on shares of Harrow in a research report on Wednesday, October 1st. Cantor Fitzgerald reissued an “overweight” rating and set a $94.00 price objective on shares of Harrow in a report on Tuesday, November 11th. HC Wainwright upped their target price on shares of Harrow from $64.00 to $69.00 and gave the company a “buy” rating in a report on Wednesday, November 12th. LADENBURG THALM/SH SH increased their target price on shares of Harrow from $64.00 to $66.00 and gave the company a “buy” rating in a research report on Wednesday, November 12th. Finally, Zacks Research raised shares of Harrow from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $71.43.

Harrow Stock Performance

Shares of HROW stock opened at $44.47 on Friday. The stock’s 50-day moving average price is $46.28 and its 200 day moving average price is $41.19. The company has a quick ratio of 2.52, a current ratio of 2.72 and a debt-to-equity ratio of 5.21. The stock has a market capitalization of $1.65 billion, a PE ratio of -444.66 and a beta of 0.02. Harrow, Inc. has a 52-week low of $20.85 and a 52-week high of $54.85.

Harrow (NASDAQ:HROW) last announced its earnings results on Monday, November 10th. The company reported $0.33 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.11. Harrow had a positive return on equity of 28.71% and a negative net margin of 1.99%.The company had revenue of $71.64 million for the quarter, compared to the consensus estimate of $73.70 million. As a group, equities research analysts forecast that Harrow, Inc. will post -0.53 EPS for the current year.

Harrow Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.